Breaking News

Galena, Teva in Commercialization Pact

December 4, 2012

To market breast cancer drug NeuVax in Israel

Galena Biopharma has signed an agreement with a subsidiary of Teva Pharmaceutical Industries for the commercialization of the breast cancer drug NeuVax in Israel. Teva Israel will assume responsibility for regulatory registration, provide financial support for development, and will commercialize the product in the region. Galena is eligible to receive royalty payments on future sales.
 
"This agreement is the first piece of our global commercialization strategy," said Mark Ahn, Ph.D., president and chief executive officer, Galena Biopharma. "Teva is a world-class pharmaceutical company and a major pharmaceutical company in Israel. We look forward to their valuable financial support towards our development goals in Israel, as well as market leadership for NeuVax commercialization in the region."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks